Uncharted waters: Navigating requests for experimental medicines
In May 2018, the federal Right-to-Try Act was signed into law, claiming a new and improved option for patients with
Read more
Dr. Christopher Scott
The perils of partnering for profit
Editor’s note: The opinions expressed in the following blog post are the author’s own and do not reflect the views
Read more
The gene therapy watchers: Can an NIH advisory committee reinvent itself?
Francis Collins, NIH Director, and Scott Gottlieb, FDA Commissioner, recently announced plans to eliminate oversight of new gene therapy experiments
Read more
CRISPR: A democratizing technology calls for democratic dialogue
By now, you may have read stories about a gene editing technique called CRISPR/Cas9. CRISPR is poised to revolutionize the
Read more
A ‘right to try,’ but at what cost?
A few weeks ago, my colleague Stephanie Morain wrote a PolicyWise post on attempts to pass so-called “right-to-try” legislation in
Read more
Life played richly: Learn to live a life of fulfillment
In her critically acclaimed one-person show, Let Me Down Easy, Anna Deavere Smith re-enacts interviews with people observing the rich
Read more
Gene therapy: An out-of-body experience
On April 1, 2016, the European Medicines Agency (EMA) approved the first ex-vivo (outside the body) gene therapy in the
Read more